Article Text

Download PDFPDF
Phase I trial of paclitaxel, doxorubicin, and carboplatin (TAC) for the treatment of endometrial cancer
  1. M. Shimada*,
  2. J. Kigawa*,
  3. N. Terakawa*,
  4. A. Yoshizaki,
  5. T. Shoji,
  6. M. Suzuki,
  7. M. Hatae§,
  8. H. Tsuda,
  9. M. Ohwada and
  10. T. Sugiyama
  1. * Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan;
  2. Department of Obstetrics and Gynecology, Iwate Medical University, Morioka, Japan;
  3. Department of Obstetrics and Gynecology, Jichi Medical School, Utsunomiya, Japan;
  4. § Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima, Japan
  5. Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka, Japan
  1. Address correspondence and reprint requests to: Toru Sugiyama, MD, PhD, Department of Obstetrics and Gynecology, Iwate Medical University, 19-1 Uchimaru, Morioka, Iwate Prefecture 020-8505, Japan. Email: sugiyama{at}


Doxorubicin, platinum compounds, and taxanes represent the chemotherapeutic agents with the greatest activity in endometrial cancer. We conducted an optimal-dose determination of combination chemotherapy consisting of paclitaxel (TXL), doxorubicin, and carboplatin (CBDCA) (TAC) in patients with endometrial cancer. Patients with epithelial endometrial cancer requiring adjuvant therapy were enrolled between June 2003 and March 2005. No patients had received prior radiotherapy, and only two patients had previously undergone chemotherapy. Doxorubicin was infused on day 1, and TXL followed by CBDCA was administered on day 2. The starting dose was doxorubicin 35 mg/m2, TXL 120 mg/m2, and CBDCA area under the curve (AUC). The dose of each agent was gradually escalated. Patients were scheduled to receive at least four cycles of therapy. If patients experienced grade 4 neutropenia or neutropenic fever with grade 3 neutropenia, they were permitted to be administered granulocyte colony–stimulating factor after the second course. Twenty-seven patients were enrolled. Although four patients out of 27 experienced dose-limiting toxicities, a maximum tolerated dose was not established at the final dose level. Five patients (three for recurrent and two for advanced) had measurable lesions. There were four responders (three for partial response and one for complete response) in our series. The recommended dose of TAC therapy for endometrial cancer was doxorubicin 45 mg/m2 for day 1, TXL 150 mg/m2 and CBDCA AUC 5 for day 2.

  • chemotherapy
  • endometrial cancer
  • TAC

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.